Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that Health Canada has approved RYBREVANT (amivantamab) in combination with chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations whose disease has progressed on osimertinib.
This approval is based on the Phase 3 MARIPOSA-2 study, which demonstrated a significant improvement in progression-free survival for patients receiving RYBREVANT plus chemotherapy compared to chemotherapy alone.
RYBREVANT offers a new treatment option for patients with EGFR-mutated NSCLC who have limited treatment options after progression on osimertinib.
Amgen's LUMAKRAS (sotorasib) in combination with Vectibix (panitumumab receives US FDA approval
Telix Pharmaceuticals' Illuccix gets European approval
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
Avacta Group reports positive data from AVA6000 Phase 1 trial in salivary gland cancer
Axcynsis Therapeutics' IND for AT03-65 receives US FDA approval
Innovent Biologics' IBI343 receives Breakthrough Therapy Designation in China
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Adaptive Biotechnologies and NeoGenomics partner to expand MRD monitoring for blood cancer
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Vascarta collaborates with City College of New York to improve efficacy and safety of chemotherapy